

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation positive non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

A potential equality issue was identified during the scoping process. The Committee noted that the reduced adverse reactions associated with tyrosine kinase inhibitors compared with those associated with chemotherapy raised during the scope consultation was not an equalities issue for this appraisal. The Committee considered the health needs of all patients included in the population under consideration in this appraisal.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equality issues were raised in the submissions, expert statements or academic report.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues were identified by the Committee.
--

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No. Given that the preliminary recommendations did not differentiate between any groups of people, the Committee concluded that its recommendations did not limit access to the technology for any specific group compared with other groups and that there was no need to alter or add to its recommendations.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

N/A

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes – section 4.18.

Approved by Associate Director: Helen Knight

Date: 10/02/2012

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues were raised during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No, the recommendations do not discriminate against any particular group in terms of access to the technology.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable. No barriers to access were identified.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's consideration of any potential equality issues is described in section 4.19 of the FAD.

Approved by Programme Director: Meindert Boysen

Date: 03/05/2012